Concert Pharmaceuticals

Concert Pharmaceuticals is an American pharmaceutical company. The сompany offers medicines and other related drug products. Concert Pharmaceuticals serves patients in the United States.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Concert Pharmaceuticals balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Concert Pharmaceuticals cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Concert Pharmaceuticals multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Concert Pharmaceuticals profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
EBITDA Margin
Operating margin
Concert Pharmaceuticals assets
Concert Pharmaceuticals cash flows

Concert Pharmaceuticals dividend policy

The company doesn't provide dividend.
Concert Pharmaceuticals news
19.01.2023
Fosun Pharmaceutical bought Concert Pharmaceuticals for $576 million, or $8 per share.
Source: {source} pictogram ir.concertpharma.com
Pictogram next
05.05.2022
Concert Pharmaceuticals' GAAP loss for 3 months of 2022 was $37.728 million, up 66.4% from $22.669 million in the previous year. The company did not earn any revenue; last year's figure was $5,000.
Source: {source} pictogram ir.concertpharma.com
Pictogram next
03.03.2022
Concert Pharmaceuticals' GAAP loss for 2021 was $80.051 million, up 7.1% from $74.766 million in the previous year. Revenue increased 4.1 times to $32.578 million from $7.902 million a year earlier.
Source: {source} pictogram ir.concertpharma.com
Pictogram next
09.11.2021
Concert Pharmaceuticals' GAAP loss for 9M 2021 was $43.922 million, down 16.1% from $52.376 million in the previous year. Revenue increased 4.1 times to $32.565 million from $7.895 million a year earlier.
Source: {source} pictogram ir.concertpharma.com
Pictogram next
All Concert Pharmaceuticals news
General information
Company nameConcert Pharmaceuticals
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address65 HAYDEN AVENUE SUITE 3000N LEXINGTON MA 02421 781-860-0045
Mailing address65 HAYDEN AVENUE SUITE 3000N LEXINGTON MA 02421
Websiteir.concertpharma.com
Information disclosurewww.sec.gov